^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
Published date:
08/28/2021
Excerpt:
In vivo studies demonstrated afatinib (30 mg/kg) and AZD9291 (25 mg/kg) could significantly reduce the LCBM in vivo and increase survival percentages of treated mice compared with mice treated with vehicle and gefitinib (6.25 mg/kg)....In conclusion, our study demonstrated gefitinib + ABT263/ABT199, afatinib, and AZD9291 have clinical potential to treat LCBM.
DOI:
10.1007/s00204-021-03147-4
